Abstract
Objective
Obesity has increased across the globe in recent years and is considered an established risk factor for many diseases. The main objective was to investigate the early assessment value of Body Mass Index (BMI) in the prediction of severity in acute biliary pancreatitis (ABP) and by using BMI to evaluate the severity of ABP.
Methods
The retrospective analysis was designed to assess the relationship between Body Mass Index and the severity of acute pancreatitis in Beijing Jishuitan Hospital from January 2019 to December 2021. The SPSS 24.0 software was used for statistical analysis, Logistic Regression, and ROC curve for the factors affecting the severity of acute biliary pancreatitis.
Results
A total of 259 ABP patients were analyzed in our study. The BMI was significantly correlated with the Ranson scoring and MCTSI scoring (p = 0.000, 0.000). The difference in BMI in different severity of ABP patients was statistically significant (p = 0.000). The Logistic Regression analyses confirmed that BMI was an independent risk factor for the severity of ABP (p = 0.035). Combined detection of BMI, WBC, serum calcium, and SAMY in prognosis of the severity of acute pancreatitis positive rate is higher than single positive rate.
Conclusion
The BMI gradually increased with the severity of acute pancreatitis and was an independent risk factor for the condition. Combined detection of BMI and medical tests can effectively improve acute pancreatitis patients' clinical diagnostic accuracy and early treatment, and help to reduce complications.
Keywords: Acute biliary pancreatitis, Obesity, BMI, Disease evaluation
Acute biliary pancreatitis; Obesity; BMI; Disease evaluation.
Acute pancreatitis is one of the leading gastrointestinal disorders that require urgent clinical treatment and increase globally in recent years [1, 2, 3]. The most common cause of AP was gallstones and alcohol consumption, hypertriglyceridemia, obesity, diabetes, smoking, drugs, endoscopic retrograde cholangiopancreatography (ERCP), trauma, and infection are also well-known suspected risk factors of pancreatitis [4, 5, 6, 7, 8, 9]. It represents a disease characterized by symptoms such as severe abdominal pain, nausea, and vomiting, which is due to the activation of various digestive enzymes [10, 11]. The clinical course of acute pancreatitis is variable, ranging from local pancreatic inflammation to consequently systemic inflammatory response, which is divided into mild acute pancreatitis (MAP), moderately severe acute pancreatitis (MSAP), and severe acute pancreatitis (SAP). Infected pancreatic necrosis and/or sepsis are major complications contributing to death at any stage [12, 13, 14, 15]. Most acute pancreatitis patients experience mild courses with early oral feeding result in rapid clinical recovery [16]. Nearly about 30% of patients may progress onto severe forms named hemorrhagic necrotizing pancreatitis or SAP, which would lead to systemic inflammatory response syndrome (SIRS), and even multiple organ dysfunction syndromeswith poor prognosis [17, 18, 19, 20]. Therefore, early diagnosis and timely treatment are critical to guide fluid resuscitation and initiate high-dependency or intensive care treatment and reduce morbidity and mortality of SAP. Early and accurate evaluation of AP severity is important to prevent progression and clinical outcomes [21, 22, 23].
With the improvement of people's living standards and the change in dietary habits, overweight and obese people have increased across the globe in recent years. Obesity is measured by body mass index (BMI, kg/m2), and is considered an established risk factor for type 2 diabetes, hyperlipidemia, and gallstone, which are all risk factors for pancreatitis [24, 25, 26, 27]. It has likely contributed to increasing the incidence and severity of acute pancreatitis [28, 29, 30, 31]. In addition, high BMI has also been directly associated with an increased risk of acute pancreatitis in some prospective studies [32]. Moreover, obese patients have a higher risk of severe acute pancreatitis. Currently, there is no uniform standard for the diagnosis of obesity all over the world, and we have adjusted the obesity judgment criteria based on BMI in China by the Chinese Society for Metabolic & Bariatric Surgery (CSMBS), which makes it more suitable for Chinese conditions. According to the latest criteria, Chinese adults define a BMI in the range of 18.5 ≤ BMI<24.9 kg/m2 as normal weight, 25.0 ≤ BMI<27.5 kg/m2 as overweight, and BMI ≥27.5 kg/m2 as obese [33, 34, 35]. Because of various definitions of BMI standards for obesity at home and abroad, this study is based on the most recent BMI standards in China to explore the judgment value of BMI and related clinical examinations in the evaluation of the early condition of acute pancreatitis. Since obesity and biliary diseases especially biliary stones are important factors causing pancreatitis, this study aimed to evaluate the clinical significance of BMI in the early assessment of the severity of acute biliary pancreatitis.
1. Methods
1.1. Patient selection
This study retrospectively included ABP cases who were admitted to Beijing Jishuitan Hospital from January 1, 2019, to December 31, 2021. The clinical features data analyzed in the study included general information such as sex, age, body mass index (BMI), history, and vital signs when admitted. Meanwhile, laboratory results, imaging tests, treatments, complications, and hospital stays. This study was approved by the Ethics Committee of the Beijing Jishuitan Hospital, and informed consent was obtained from all individuals.
2. Standards of diagnosis
2.1. Diagnostic criteria for acute pancreatitis
The diagnosis and classification of the severity of AP were defined according to the 2012 revision of the Atlanta Classification [14]. The diagnosis of AP requires 2 of the following 3 features: (1) abdominal pain consistent with the disease (2) serum lipase activity (or amylase activity) at least three times greater than the upper limit of normal; and (3) characteristic findings from abdominal imaging. Disease severity was graded as mild or moderately severe, based on the presence of local or systemic complications and transient/persistent organ failure. The diagnostic criteria of acute biliary pancreatitis (ABP) were as follows: the patients were grouped under the diagnostic criteria of AP, imaging examination found gallbladder stones and/or bile duct stones, and laboratory exams showed increased levels of ALT and bilirubin [36].
2.2. Ranson score
The Ranson score was the first specific multifactorial scoring system for patients with AP published in 1974 and modified in 1979 by Ranson. It consists of 11 parameters identified as significant prognostic factors: Five parameters measured at admission and six during the next 48 h. Present on admission: (1) Age >55 years, (2) WBC >16000/mm3, (3) Glucose >11.1 mmol/L, (4) LDH >350U/L, (5) AST >250 U/L; During the first 48 h: (1) Hematocrit decrease >10% points, (2) BUN increase >1.79 mmol/L, (3) Serum calcium <2 mmol/L, (4) PaO2 <60mmHg, (5) Base deficit > 4 mmol/L, (6) Fluid sequestration >6L. Mortality increases with an increasing score. A score between 1 to 3 criteria represents mild AP; the mortality rate rises significantly with four or more criteria, being 100% in those with six or more [37, 38].
2.3. Modified CT severity index (MCTSI) scoring criteria
The degree of AP was also obtained by the established CT severity index (CTSI) developed by Balthazar et al. and the modified CT severity index (MCTSI) by Mortele et al [39, 40] (Table 1). For the MCTSI, the morphologic severity of pancreatitis was categorized as mild (0–2 points), moderate (4–6 points), or severe (8–10 points). The MCTSI was easy to calculate, and more accurately to judge the severity of infection, organ failure, the length of hospital stays, and death [41, 42, 43]. Each score was applied independently to the investigated CT studies by both observers, who were blinded to all clinical parameters and the scoring results of their counterparts.
Table 1.
Modified CTSI (MCTSI) score.
| Characteristics | MCTSI (0–10) |
|---|---|
| Pancreatic inflammation | |
| Normal pancreas | 0 |
| Focal or diffuse enlargement of pancreas | 2 |
| Peripancreatic inflammation | 2 |
| Single acute fluid collection | 4 |
| Two or more acute fluid collections | 4 |
| Pancreatic parenchymal necrosis | |
| None | 0 |
| Less than 30% | 2 |
| Between 30% and 50% | 4 |
| More than 50% | 4 |
| Extrapancreatic complicationsa | 3 |
One or more of pleural effusion, ascites, vascular complications, parenchymal complications, or gastrointestinal tract involvement.
2.4. Statistical analysis
The categorical variables are presented as numbers and continuous variables are presented as medians and mean differences. The categorical variables were statistically compared by the chi-square ×2 test. The Mann-Whitney U-test and t-test were used for continuous variables and measurement data. The logistic regression model was used to determine the independent factors for variables with significance in the univariate and multivariate analyses. The logistic regression was done by forward step-wise and wald p-value. The results are expressed as odds ratios (ORs) with 95% confidence intervals (CIs). The ROC curve was used for predicting SAP sensitivity analysis. P < 0.05 was considered as the significance level. SPSS 24.0 statistical software was used for all data analysis.
3. Results
A total of 259 patients with ABP were admitted to the study. There were 138 males (53.3%) and 121 females (46.7%). The mean age was 60.98 ± 1.03 (19–97) years for all AP patients. The mean BMI of the patients was 25.97 ± 0.23 (18.79–38.67) kg/m2. According to the Chinese criteria, the number of obese patients of ABP was 99 (38.2%), the overweight patients were 61 (23.6%), and the normal weight patients were 99 (38.2%). The MAP patients were 115 (44.4%), the MSAP cases were 106 (40.9%), and the SAP cases were 38 (14.7%).
3.1. The relationship between BMI and ranson score, MCTSI score in ABP patients
The BMI was significantly correlated with the Ranson score for ABP patients (p = 0.000), and the results showed that the higher the Ranson score, the higher the proportion of patients with high BMI. Similarly, the BMI was also significantly correlated with the MCTSI score (p = 0.000), and the difference was statistically significant. The higher the Ranson score, the higher the proportion of ABP patients with high BMI (Table 2).
Table 2.
The relationship between BMI, Ranson score and MCTSI score in ABP.
| Scores | BMI (kg/m2) |
p | ||
|---|---|---|---|---|
| <25 | 25–27.4 | ≥27.5 | ||
| Ranson | ||||
| <3 | 47 (47.5%) | 17 (27.9%) | 23 (23.2%) | 0.000∗ |
| 3–4 | 40 (40.4%) | 28 (45.9%) | 40 (40.4%) | |
| >4 | 12 (12.1%) | 16 (26.2%) | 36 (36.4%) | |
| <3 | 47 (47.5%) | 17 (27.9%) | 23 (23.2%) | 0.000∗ |
| ≥3 | 52 (52.5%) | 44 (72.1%) | 76 (76.8%) | |
| MCTSI | ||||
| ≤3 | 54 (54.5%) | 27 (44.3%) | 26 (26.3%) | 0.000∗ |
| 4–6 | 40 (40.4%) | 23 (37.7%) | 55 (55.6%) | |
| ≥7 | 5 (5.1%) | 11 (18.0%) | 18 (18.2%) | |
| ≤3 | 54 (54.5%) | 27 (44.3%) | 26 (26.3%) | 0.000∗ |
| ≥4 | 45 (45.5%) | 34 (55.7%) | 73 (73.7%) | |
3.2. The analyses of risk factors for the severity of ABP pancreatitis
The analysis was performed to evaluate the risk factors for the severity of acute pancreatitis. The BMI, Ranson score, MCTSI score, Recurrence, Live or not, and clinical complications were experienced higher in different severity of ABP patients, and the difference was statistically significant (p = 0.000, 0.000, 0.000, 0.024, 0.000, 0.000). And the length of stay in the hospital was significantly longer for MSAP and SAP (p = 0.003). With the gradual severity of ABP, the BMI level, WBC, AST, DBIL, blood glucose, UREA, LDH, D-dimer, serum amylase, and C-reactive protein (CRP) were significantly increased (p = 0.000, 0.000, 0.006, 0.034, 0.010, 0.031, 0.000, 0.000, 0.000 and 0.010), and the serum calcium level was significantly decreased (p = 0.000), the difference was statistically significant. But there were no significant differences with sex, age, fatty liver, ALT, TBIL, CREA, triglyceride, total cholesterol, urinary amylase, and PCT (p > 0.05, Table 3). For further study, we divided the ABP patients into two groups including MAP and MSAP/SAP group, and we found that the severity of ABP were significantly associated with BMI, WBC, AST, blood glucose, UREA, CREA, Calcium, LDH, D-dimer, serum amylase, and C-reactive protein (CRP) were significantly increased (p = 0.000, 0.000, 0.007, 0.002, 0.003, 0.023, 0.000, 0.001, 0.000 and 0.017). In the multivariate analysis, the BMI (p = 0.035), WBC (p = 0.025), serum calcium level (p = 0.030), and serum amylase level (p = 0.020) were all verified as independent risk factors for the severity of ABP (Table 4).
Table 3.
The analysis of the risk factors for the severity of ABP.
| Variables | Acute Biliary Pancreatitis |
p | ||
|---|---|---|---|---|
| MAP (n = 115) | MSAP (n = 106) | SAP (n = 38) | ||
| Sex | 0.653 | |||
| Male | 58 (50.4%) | 60 (56.6%) | 20 (52.6%) | |
| Female | 57 (49.6%) | 46 (43.4%) | 18 (47.4%) | |
| Age(years) | 0.096 | |||
| <63 | 63 (54.8%) | 48 (45.3%) | 16 (42.1%) | |
| ≥63 | 52 (45.2%) | 58 (54.7%) | 22 (57.9%) | |
| BMI(kg/m2) | ||||
| <25.0 | 61 (53.0%) | 34 (32.1%) | 4 (10.5%) | 0.000∗ |
| 25.0～27.4 | 28 (24.3%) | 21 (19.8%) | 12 (31.6%) | |
| ≥27.5 | 26 (22.6%) | 51 (48.1%) | 22 (57.9%) | |
| <27.5 | 89 (77.4%) | 55 (51.9%) | 16 (42.1%) | 0.000∗ |
| ≥27.5 | 26 (22.6%) | 51 (48.1%) | 22 (57.9%) | |
| Ranson | ||||
| <3 | 78 (67.8%) | 9 (8.5%) | 0 (0.0%) | 0.000∗ |
| 3–4 | 36 (31.3%) | 65 (61.3%) | 7 (18.4%) | |
| >4 | 1 (0.9%) | 32 (30.2%) | 31 (81.6%) | |
| <3 | 78 (67.8%) | 9 (8.5%) | 0 (0.0%) | 0.000∗ |
| ≥3 | 37 (32.2%) | 97 (91.5%) | 38 (100.0%) | |
| MCTSI | ||||
| ≤3 | 99 (86.1%) | 8 (7.5%) | 0 (0.0%) | 0.000∗ |
| 4–6 | 16 (13.9%) | 95 (89.6%) | 7 (18.4%) | |
| ≥7 | 0 (0.0%) | 3 (2.8%) | 31 (81.6%) | |
| ≤3 | 99 (86.1%) | 8 (7.5%) | 0 (0.0%) | 0.000∗ |
| >3 | 16 (13.9%) | 98 (92.5%) | 38 (100.0%) | |
| Recurrence | 0.024∗ | |||
| Yes | 23 (20.0%) | 37 (34.9%) | 14 (36.8%) | |
| No | 92 (80.0%) | 69 (65.1%) | 24 (63.2%) | |
| Live | 0.000∗ | |||
| Yes | 115 (100.0%) | 106 (100.0%) | 34 (89.5%) | |
| No | 0 (0.0%) | 0 (0.0%) | 4 (10.5%) | |
| Complication | 0.000∗ | |||
| No | 51 (44.3%) | 24 (22.6%) | 3 (7.9%) | |
| Yes | 64 (55.7%) | 82 (77.4%) | 35 (92.1%) | |
| Fatty Liver | 0.952 | |||
| No | 88 (76.5%) | 82 (77.4%) | 30 (78.9%) | |
| Yes | 27 (23.5%) | 24 (22.6%) | 8 (21.1%) | |
| Stay in Hospital (Days) | 10.04 ± 0.41 | 10.81 ± 0.42 | 16.39 ± 2.29 | 0.003∗ |
| BMI (kg/m2) | 24.80 ± 0.35 | 26.63 ± 0.37 | 27.66 ± 0.38 | 0.000∗ |
| Age (years) | 58.83 ± 1.57 | 63.03 ± 1.62 | 61.79 ± 2.37 | 0.147 |
| WBC (×109/L) | 10.63 ± 0.34 | 13.08 ± 0.41 | 15.43 ± 0.72 | 0.000∗ |
| ALT (IU/L) | 206.32 ± 19.65 | 249.98 ± 21.44 | 231.16 ± 37.80 | 0.124 |
| AST (IU/L) | 224.84 ± 24.09 | 337.71 ± 34.95 | 332.29 ± 67.41 | 0.006∗ |
| TBIL (μmol/L) | 44.89 ± 3.97 | 45.39 ± 3.40 | 57.90 ± 9.31 | 0.147 |
| DBIL (μmol/L) | 24.81 ± 2.77 | 24.45 ± 1.84 | 35.72 ± 6.72 | 0.034∗ |
| Glucose (mmol/L) | 8.24 ± 0.27 | 9.48 ± 0.34 | 9.56 ± 0.54 | 0.010∗ |
| UREA (mmol/L) | 5.32 ± 0.18 | 5.92 ± 0.20 | 7.73 ± 1.00 | 0.031∗ |
| CREA (μmol/L) | 66.94 ± 1.72 | 70.18 ± 2.13 | 91.24 ± 11.35 | 0.104 |
| Calcium (mmol/L) | 2.23 ± 0.02 | 2.15 ± 0.02 | 2.00 ± 0.03 | 0.000∗ |
| TG (mmol/L) | 1.87 ± 0.32 | 1.71 ± 0.29 | 1.69 ± 0.26 | 0.328 |
| CHOI (mmol/L) | 4.74 ± 0.14 | 4.71 ± 0.26 | 4.31 ± 0.20 | 0.280 |
| LDH (IU/L) | 289.12 ± 18.69 | 366.23 ± 26.55 | 468.92 ± 59.96 | 0.000∗ |
| D-dimer (μg/L) | 2.00 ± 0.39 | 2.98 ± 0.57 | 3.72 ± 0.68 | 0.000∗ |
| Serum Amylase (U/L) | 1020.87 ± 82.59 | 1672.71 ± 119.09 | 1416.21 ± 191.63 | 0.000∗ |
| Urinary Amylase (U/L) | 6631.26 ± 982.28 | 8788.60 ± 1587.15 | 6976.19 ± 1206.41 | 0.106∗ |
| CRP (mg/L) | 18.19 ± 5.13 | 31.92 ± 5.91 | 47.85 ± 11.28 | 0.010∗ |
| PCT (μg/L) | 2.44 ± 0.65 | 2.39 ± 0.64 | 2.86 ± 0.76 | 0.577 |
Table 4.
The multivariate analysis of the risk factors for the severity of ABP.
| Variables | p | OR |
|---|---|---|
| BMI | 0.035 | 3.46 (1.09–11.03) |
| WBC (×109/L) | 0.025 | 1.21 (1.02–1.44) |
| Calcium (mmol/L) | 0.30 | 0.05 (0.00–0.74) |
| Serum Amylase (U/L) | 0.20 | 1.00 (1.00–0.1.00) |
3.3. The diagnostic value of BMI, WBC, serum calcium, and serum amylase in the severity of ABP
The ROC curve showed that BMI, WBC, serum calcium and serum amylase had certain diagnostic values for the different severity of ABP, but combined examination of the four factors had the highest diagnostic value, with the Area Under Curve (AUC) of 0.887 and the sensitivity of 77.5% and the specificity of 85.7% (Table 5, Figure 1).
Table 5.
The diagnostic value of BMI, WBC, serum calcium and serum amylase in the severity of ABP.
| Variables | Cutoff value | Sensitivity | Specificity | AUC |
|---|---|---|---|---|
| BMI (kg/m2) | 25.96 | 0.648 | 0.653 | 0.673 (0.576–0.771) |
| WBC (×109/L) | 11.77 | 0.648 | 0.694 | 0.726 (0.636–0.816) |
| Calcium (mmol/L) | 2.14 | 0.648 | 0.653 | 0.320 (0.224–0.415) |
| Serum Amylase (U/L) | 1182.50 | 0.606 | 0.633 | 0.667 (0.571–0.762) |
| Combined Test | 0.775 | 0.857 | 0.887 (0.810–0.934) |
Figure 1.
The ROC curve for BMI, WBC, serum calcium, serum amylase and combined test in the severity of ABP.
4. Discussion
Acute pancreatitis is a common acute abdominal disease, as an inflammatory disorder of the pancreas. It takes a great economic cost for a lot of hospital admissions, especially for moderately severe and severe AP [44]. For this reason, the determination of the severity of AP in early stage is crucial for achieving good clinical outcomes and reducing costs. Until now, there are many different scoring systems for the severity of acute pancreatitis, including the Ranson score, MCTSI score, BISAP score, APACHE-II scores, et al [45, 46, 47, 48]. The severity of AP can be predicted based on clinical, laboratory, radiology, and biomarkers. However, the evaluation process of these scoring systems is too cumbersome, especially for the early judgment of SAP, and some coring systems could only be estimated 48 h or more after admission. The good predictor should be rapid, inexpensive, and easy to be implemented. With the improvement of people’s living standards and changes in eating habits, the incidence of biliary tract diseases is getting higher and higher, and the resulting biliary pancreatitis is also gradually increasing. Therefore, we must evaluate the condition of ABP as soon as possible.
The serological test is simple and fast, easy for dynamic observation, and has good clinical application value. At present, the most commonly used diagnostic indicator for ABP is serum amylase, but serum amylase also tends to increase in patients with other abdominal diseases such as some biliary diseases, hepatitis, or tumors, while serum amylase in patients with pancreatic necrosis does not find an abnormal increase, and it is not directly proportional to the severity of the disease. Consequently, serum amylase is not the only index to judge the condition of ABP [49]. The ABP patients with severe stage often have elevated body temperature, elevated leukocytes, and organ dysfunction. Thus, the level of serum white blood cells (WBC) is an important reference factor to evaluate the condition of AP patients. In a prospective and multicenter study, the WBC and CRP level with in 24h from the onset of pain were significantly lower in mild and moderately severe than in severe AP [50]. A similar result for WBC and CRP was found in our study, but not for PCT, although the severe patients had a higher level of PCT. The decrease in serum calcium level is correlated with the severity of AP, and it is one of the sensitive factors to evaluate the severity of AP [51]. Low serum calcium level has been demonstrated that it played as an important role in judging patients with severe AP, which was verified as an independent risk factor [52, 53]. In our study, we also observed that the severity of ABP was not only significantly related to the Ranson score and MCTSI score but also closely related to the patient's WBC level, liver and kidney function, blood glucose, calcium, amylase, and other serological tests. These are similar to previous findings.
With the change in people's lifestyle and dietary habits in recent years, the number of overweight and obese people is increasing. The BMI has become one of the most widely used evaluate the degree of obesity. Previous studies have shown that obesity is closely related to a variety of diseases, and more and more studies have shown that it may be related to the severity of acute pancreatitis, but fewer in China [54, 55, 56]. Lankisch PG et al. introduced BMI into acute pancreatitis for the first time in 1990, and proposed that obese patients were related to the acute occurrence of metabolic abnormalities, cholecystitis, hyperlipidemia, and acute pancreatitis [57]. De Waele et al. have shown that being overweight and obese can obviously promote the occurrence of various complications of acute pancreatitis and are high-risk factors for severe patients [58]. To date, one prospective study (68,158 participants and 424 cases) has investigated the association of both BMI and Waist circumference (WC) with acute pancreatitis [59]. Most obese patients have a large amount of fat accumulation around the abdominal viscera. A lot of fat accumulated around the pancreas provides the basis for pancreatic bleeding, necrosis, and saponification. Fat decomposition releases a large amount of free fatty acids, which in turn damages pancreatic acinar cells and capillaries and accelerates the activation of trypsinogen, In addition, free fatty acids and chyle particles can block pancreatic capillaries, easily form microthrombosis, block pancreatic blood vessels, lead to pancreatic microcirculation disorder, release a variety of inflammatory factors, aggravate systemic inflammatory response syndrome, and easily complicated with multiple organ failure. The condition of acute pancreatitis in obese patients may be more serious and the incidence of complications is higher [60, 61, 62, 63]. Consistent with these previous studies, the BMI level of ABP patients is not only closely related to the Ranson score and MCTSI score of patients, but also the higher proportion of overweight and obese patients with the increase of score, and it is more prone to complications in our observations. The latest study showed that the obese patients carried an increased risk for longer hospitalization, morbidity, and mortality [64]. Although hypertriglyceridemia is a more common cause of acute pancreatitis, and its prevalence is higher in obese and overweight individuals, the severity of disease and clinical outcomes are not significantly associated with it [65]. Our study supports this view, but it remains controversial [66, 67]and one of the reasons may be that the number of ABP patients in this study is too small. Moreover, BMI is also an independent risk factor for the severity of a patient's condition, which also confirms the above view. Furthermore, according to these independent factors, we combined the BMI level, serum WBC, calcium, and amylase to predict the severity of ABP with good sensitivity and specificity. This provides a good method for early judgment of the severity of ABP in the future. However, there are several limitations to the study. This study is a retrospective single-center study, and it has a certain deviation in case screening. We expect to conduct a larger-sample, multicenter research to improve the reliability and value of the combined factors in future research.
5. Conclusion
In conclusion, patients with high BMI are more likely to develop more serious acute biliary pancreatitis. BMI is an independent risk factor for the severity of acute pancreatitis. Combined detection of BMI, serum WBC, calcium, and amylase levels will help to improve the early judgment of SAP, more conducive to early and timely detection and treatment, further reducing complications and mortality.
Declarations
Author contribution statement
Zhixue Zheng: Conceived and designed the experiments; Analyzed and interpreted the data; Wrote the paper.
Jing Tao Bi: Analyzed and interpreted the data.
Xuan Cai and Ya Qi Liu: Contributed regents, materials, and data.
Funding statement
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Data availability statement
Data included in article/supp. material/referenced in article.
Declaration of interest’s statement
The authors declare no conflict of interest.
Additional information
No additional information is available for this paper.
References
- 1.Peery A.F., Crockett S.D., Barritt A.S., et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States[J] Gastroenterology. 2015;149:1731–1741. doi: 10.1053/j.gastro.2015.08.045. e1733. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Petrov M.S., Yadav D. Global epidemiology and holistic prevention of pancreatitis[J] Nat. Rev. Gastroenterol. Hepatol. 2019;16:175–184. doi: 10.1038/s41575-018-0087-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Peery A.F., Crockett S.D., Murphy C.C., et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018 [J] Gastroenterology. 2019;156(1) doi: 10.1053/j.gastro.2018.08.063. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.van Geenen E.J., van der Peet D.L., Bhagirath P., et al. Etiology and diagnosis of acute biliary pancreatitis[J] Nat. Rev. Gastroenterol. Hepatol. 2010;7:495–502. doi: 10.1038/nrgastro.2010.114. [DOI] [PubMed] [Google Scholar]
- 5.Zheng Zhi, Ding Yi-Xuan, Qu Yuan-Xu, et al. A narrative review of acute pancreatitis and its diagnosis, pathogenetic mechanism, and management[J] Ann. Transl. Med. 2021;9(1):69. doi: 10.21037/atm-20-4802. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Roberts S.E., Morrison-Rees S., John A., et al. The incidence and aetiology of acute pancreatitis across Europe[J] Pancreatology. 2017;17:155–165. doi: 10.1016/j.pan.2017.01.005. [DOI] [PubMed] [Google Scholar]
- 7.Boxhoorn L., Voermans R.P., Bouwense S.A., et al. Acute pancreatitis[J] Lancet. 2020;396:726–734. doi: 10.1016/S0140-6736(20)31310-6. [DOI] [PubMed] [Google Scholar]
- 8.Pang Y., Kartsonaki C., Turnbull I., et al. Metabolic and lifestyle risk factors for acute pancreatitis in Chinese adults: a systematic review and metaanalysis[J] Pancreas. 2015;44:540–546. [Google Scholar]
- 9.Pang Y., Kartsonaki C., Turnbull I., et al. Metabolic and lifestyle risk factors for acute pancreatitis in Chinese adults: a prospective cohort study of 0.5 million people[J] PLoS Med. 2018;15 doi: 10.1371/journal.pmed.1002618. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Muniraj T., Aslanian H.R., Farrell J., Jamidar P.A. Chronic pancreatitis, a comprehensive review and update. Part I: epidemiology, etiology, risk factors, genetics, pathophysiology, and clinical features[J] Dis. Mon. 2014;60:530–550. doi: 10.1016/j.disamonth.2014.11.002. [DOI] [PubMed] [Google Scholar]
- 11.Hammad A.Y., Ditillo M., Castanon L. Pancreatitis[J] Surg. Clin. 2018;98:895–913. doi: 10.1016/j.suc.2018.06.001. [DOI] [PubMed] [Google Scholar]
- 12.Dellinger E.P., Forsmark C.E., Layer P., et al. Pancreatitis across Nations Clinical Research and Education Alliance (PANCREA). Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation[J] Ann. Surg. 2012;256:875–880. doi: 10.1097/SLA.0b013e318256f778. [DOI] [PubMed] [Google Scholar]
- 13.Guo Q., Li A., Xia Q., et al. The role of organ failure and infection in necrotizing pancreatitis: a prospective study[J] Ann. Surg. 2014;259:1201–1207. doi: 10.1097/SLA.0000000000000264. [DOI] [PubMed] [Google Scholar]
- 14.Banks P.A., Bollen T.L., Dervenis C., et al. Acute pancreatitis classification working G. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus[J] Gut. 2013;62(1):102–111. doi: 10.1136/gutjnl-2012-302779. [DOI] [PubMed] [Google Scholar]
- 15.Leppäniemi A., Tolonen M., Tarasconi A., et al. WSES guidelines for the management of severe acute pancreatitis[J] World J. Emerg. Surg. 2019;14:27. doi: 10.1186/s13017-019-0247-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.van Santvoort H.C., Bakker O.J., Bollen T.L., et al. A conservative and minimally invasive approach to necrotizing pancreatitis improves outcome[J] Gastroenterology. 2011;141:1254–1263. doi: 10.1053/j.gastro.2011.06.073. [DOI] [PubMed] [Google Scholar]
- 17.Al Mofleh I.A. Severe acute pancreatitis: pathogenetic aspects and prognostic factors[J] World J. Gastroenterol. 2008;14:675–684. doi: 10.3748/wjg.14.675. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Frossard J.L., Steer M.L., Pastor C.M. Acute pancreatitis[J] Lancet. 2008;371:143–152. doi: 10.1016/S0140-6736(08)60107-5. [DOI] [PubMed] [Google Scholar]
- 19.van Dijk S.M., Hallensleben N.D.L., van Santvoort H.C., et al. Acute pancreatitis: recent advances through randomised trials[J] Gut. 2017;66:2024–2032. doi: 10.1136/gutjnl-2016-313595. [DOI] [PubMed] [Google Scholar]
- 20.Dellinger E.P., Forsmark C.E., Layer P., et al. Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation[J] Ann. Surg. 2012;256:875–880. doi: 10.1097/SLA.0b013e318256f778. [DOI] [PubMed] [Google Scholar]
- 21.Milian J.W., Portugal S.J., Laynez Ch R., et al. Necrotic acute pancreatitis in the intensive care unit: a comparison between conservative and surgical medical treatment[J] Rev. Gastroenterol. Peru. 2010;30:195–200. [in Spanish, English abstract] [PubMed] [Google Scholar]
- 22.Guo Q., Li A., Xia Q., et al. The role of organ failure and infection in necrotizing pancreatitis: a prospective study[J] Ann. Surg. 2014;259:1201–1207. doi: 10.1097/SLA.0000000000000264. [DOI] [PubMed] [Google Scholar]
- 23.Dimagno M.J., Wamsteker E.J., Rizk R.S., et al. A combined paging alert and web-based instrument alters clinician behavior and shortens hospital length of stay in acute pancreatitis[J] Am. J. Gastroenterol. 2014;109:306–315. doi: 10.1038/ajg.2013.282. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Abdullah A., Peeters A., de Court, Stoelwinder J. The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies[J] Diabetes Res. Clin. Pract. 2010;89:309–319. doi: 10.1016/j.diabres.2010.04.012. [DOI] [PubMed] [Google Scholar]
- 25.Aune D., Norat T., Vatten L.J. Body mass index, abdominal fatness and the risk of gallbladder disease[J] Eur. J. Epidemiol. 2015;30:1009–1019. doi: 10.1007/s10654-015-0081-y. [DOI] [PubMed] [Google Scholar]
- 26.Hansen S.E.J., Madsen C.M., Varbo A., Nordestgaard B.G. Body mass index, triglycerides, and risk of acute pancreatitis: a population-based study of 118,000 individuals[J] J. Clin. Endocrinol. Metab. 2020;105:2020. doi: 10.1210/clinem/dgz059. [DOI] [PubMed] [Google Scholar]
- 27.Curry S.J., Krist A.H., Owens D.K., et al. Behavioral weight loss interventions to prevent obesity-related morbidity and mortality in adults: US Preventive Services Task Force Recommendation Statement[J] JAMA. 2018;320(11):1163–1171. doi: 10.1001/jama.2018.13022. [DOI] [PubMed] [Google Scholar]
- 28.Peery A.F., Crockett S.D., Barritt A.S., et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States[J] Gastroenterology. 2015;149 doi: 10.1053/j.gastro.2015.08.045. 1731.e3-1731.e1741. e3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.O’Leary D.P., O’Neill D., McLaughlin P., et al. Effects of abdominal fat distribution parameters on severity of acute pancreatitis[J] World J. Surg. 2012;36:1679–1685. doi: 10.1007/s00268-011-1414-y. [DOI] [PubMed] [Google Scholar]
- 30.Chen S.M., Xiong G.S., Wu S.M. Is obesity an indicator of complications and mortality in acute pancreatitis? An updated meta-analysis[J] J. Dig. Dis. 2012;13:244–251. doi: 10.1111/j.1751-2980.2012.00587.x. [DOI] [PubMed] [Google Scholar]
- 31.Khatua Biswajit, El-Kurdi Bara, Singh Vijay P. Obesity and pancreatitis[J] Curr. Opin. Gastroenterol. 2017;33(5):374–382. doi: 10.1097/MOG.0000000000000386. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Antonopoulos A.S., Oikonomou E.K., Antoniades C., et al. From the BMI paradox to the obesity paradox: the obesity–mortality association in coronary heart disease[J] Obes. Rev. 2016;17(10):989–1000. doi: 10.1111/obr.12440. [DOI] [PubMed] [Google Scholar]
- 33.Zhang Peng, Zheng Chengzhu, Torquati Alfonso, et al. The similarities and differences between the current status of Metabolic & Bariatric Surgery in the United States and China[J] Chin J Pract Surg. 2014;34(11):1094–1096. [in Chinese] [Google Scholar]
- 34.Chinese Society for Metabolic & Bariatric Surgery Guidelines for surgical treatment of obesity and type 2 diabetes in China (2014)[J] Chin. J. Pract. Surg. 2014;34(11):1005–1010. [in Chinese] [Google Scholar]
- 35.Chinese Society for Metabolic & Bariatric Surgery Guidelines for surgical treatment of obesity and type 2 diabetes in China (2019)[J] Chin. J. Pract. Surg. 2019;39(4):301–306. [in Chinese] [Google Scholar]
- 36.Dellinger E.P., Forsmark C.E., Layer P., et al. Determinant-based classification of acute pancreatitis severity: an international multidisciplinary consultation[J] Ann. For. 2012;256(6):875–880. doi: 10.1097/SLA.0b013e318256f778. [DOI] [PubMed] [Google Scholar]
- 37.Ranson J.H., Rifkind K.M., Roses D.F., et al. Prognostic signs and the role of operative management in acute pancreatitis[J] Surg. Gynecol. Obstet. 1974;139:69–81. [PubMed] [Google Scholar]
- 38.Ranson J.H. The timing of biliary surgery in acute pancreatitis[J] Ann. Surg. 1979;189:654–663. doi: 10.1097/00000658-197905000-00016. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Balthazar E.J., Robinson D.L., Megibow a J., Ranson J.H. Acute pancreatitis: value of CT in establishing prognosis[J] Radiology. 1990;174(2):331–336. doi: 10.1148/radiology.174.2.2296641. [DOI] [PubMed] [Google Scholar]
- 40.Mortele K.J., Shankar S., Zou K.H., et al. A modified CT severity index for evaluating acute pancreatitis: improved correlation with patient outcome[J] Am. Journal. Rev. 2004;183:1261–1265. doi: 10.2214/ajr.183.5.1831261. [DOI] [PubMed] [Google Scholar]
- 41.Thomas L.B., Vikesh K.S., Maurer Rie, et al. Comparative evaluation of the modified CT severity index and CT severity index in assessing severity of acute pancreatitis[J] Am. Journal. Rev. 2011;197:386–392. doi: 10.2214/AJR.09.4025. [DOI] [PubMed] [Google Scholar]
- 42.Raghuwanshi S., Gupta R., Vyas M.M., Sharma R. CT evaluation of acute pancreatitis and its prognostic correlation with CT severity index[J] J. Clin. Diagn. Res. 2016;10:Tc06–11. doi: 10.7860/JCDR/2016/19849.7934. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Avanesov M., Löser A., Smagarynska A., et al. Clinico-radiological comparison and short-term prognosis of single acute pancreatitis and recurrent acute pancreatitis including pancreatic volumetry[J] PLoS One. 2018;13(10) doi: 10.1371/journal.pone.0206062. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.van Dijk S.M., Hallensleben N.D., van Santvoort H.C., et al. Acute pancreatitis: recent advances through randomized trials[J] Gut. 2017;66:2024–2032. doi: 10.1136/gutjnl-2016-313595. [DOI] [PubMed] [Google Scholar]
- 45.Dambrauskas Z., Gulbinas A., Pundzius J., et al. Value of the different prognostic systems and biological markers for predicting severity and progression of acute pancreatitis[J] Scand. J. Gastroenterol. 2010;45(7-8):959–970. doi: 10.3109/00365521003770244. [DOI] [PubMed] [Google Scholar]
- 46.Wang Dong-xu, Lin Lian-jie, Yan L.I.N., et al. Clinical value of bedside index for severity in acute pancreatitis scoring system to predicting severity and prognosis of acute pancreatitis[J] Chin. J. Pract. Diag. Ther. 2014;(28):672–673. [Google Scholar]
- 47.Harshit Kumar A., Singh Griwan M. A comparison of Apache II, BISAP, Ranson’s score and modified CTSI in predicting the severity of acute pancreatitis based on the 2012 revised Atlanta Classification[J] Gastroenterol. Rep. 2018;6:127–131. doi: 10.1093/gastro/gox029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Zheng L., Hong W., Geng W., et al. A comparison of the BISAP score and Amylase and BMI (CAB) score versus for predicting severe acute pancreatitis[J] Acta Gastro. Enterol. Belg. 2019;82:397–400. [PubMed] [Google Scholar]
- 49.Li Jing-min, Chen Yan-zhi, Xu liu-qin. The application of combined detection of serum amylase and lipase in the diagnosis of acute pancreatitis[J] Internet J. Lab. Med. 2011;32(21):2503–2504. [Google Scholar]
- 50.Farkas N., Hanák L., Mikó A., et al. A multicenter, international cohort analysis of 1435 cases to support clinical trial design in acute pancreatitis[J] Front. Physiol. 2019;10 doi: 10.3389/fphys.2019.01092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Huang Rui, Liu Nian. The value of PCT, calcium, CRP and lipase in predicting the severity of acute pancreatitis[J] J Hepato. Surg. 2019;27(6):422–425. [Google Scholar]
- 52.Huai J., Shao Y., Sun X., et al. Melatonin ameliorates acute necrotizing pancreatitis by the regulation of cytosolic Ca2+ homeostasis[J] Pancreatology. 2012;12:257–263. doi: 10.1016/j.pan.2012.02.004. [DOI] [PubMed] [Google Scholar]
- 53.Yu S., Wu D., Jin K., et al. Low serum ionized calcium, elevated high-sensitivity C-reactive protein, neutrophil-lymphocyte ratio, and body mass index (BMI) are risk factors for severe acute pancreatitis in patients with hypertriglyceridemia pancreatitis[J] Med. Sci. Monit. Int. Med. J. Exp. Clin. Res. 2019;25:6097–6103. doi: 10.12659/MSM.915526. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Premkumar R., Phillips A.R., Petrov M.S., et al. The clinical relevance of obesity in acute pancreatitis: targeted systematic reviews[J] Pancreatology. 2015;15(1):25–33. doi: 10.1016/j.pan.2014.10.007. [DOI] [PubMed] [Google Scholar]
- 55.Yang Li-xin, Chen Jing, Du Li-chuan, et al. Correlation between severity and complications of hyperlipidemic acute pancreatitis and body mass index and waist hip ratio[J] China J. Mod. Med. 2016;26(24):129–132. [Google Scholar]
- 56.Ikeura T., Kato K., Takaoka M., et al. A body mass index >/=25 kg/m(2) is associated with a poor prognosis in patients with acute pancreatitis: a study of Japanese patients[J] Hepatobiliary Pancreat. Dis. Int. 2017;16(6):645–651. doi: 10.1016/S1499-3872(17)60057-2. [DOI] [PubMed] [Google Scholar]
- 57.Lankisch P.G., Schirren C.A. Increased body weight as a prognostic parammeter for complications in the course of acute pancreatitis[J] Pancreas. 1990;5(5):626–629. doi: 10.1097/00006676-199009000-00021. [DOI] [PubMed] [Google Scholar]
- 58.De Waele B., Vanmierlo B., Van Nieuwenhove Y., et al. Impact of body overweight and class Ⅰ, Ⅱ and Ⅲ obesity on the outcome of acute biliary pancreatitis[J] Pancreas. 2006;32(4):343–345. doi: 10.1097/01.mpa.0000220857.55378.7b. [DOI] [PubMed] [Google Scholar]
- 59.Sadr-Azodi O., Orsini N., Andre´n-Sandberg Å., Wolk A. Abdominal and total adiposity and the risk of acute pancreatitis: a population-based prospective cohort study[J] Am. J. Gastroenterol. 2013;108(1):133–139. doi: 10.1038/ajg.2012.381. [DOI] [PubMed] [Google Scholar]
- 60.Jaworek J., Bonior J., Pierzchalski P., et al. Leptin protects the pancreas from damage induced by caerulein overstimulation bymodulating cytokine production[J] Pancreatology. 2002;2(2):89–99. doi: 10.1159/000055897. [DOI] [PubMed] [Google Scholar]
- 61.Xiao-Ling D.I.N.G., Guo-Xiong Z.H.O.U., Cao Liang. A study on correlation between obesity and hyperlipemia and acute pancreatitis[J] Chin. J. Pancreatol. 2004;4(1):23–25. [Google Scholar]
- 62.Sempere L., Martinez J., De Madaria E., et al. Obesity and fat distribution imply a greater systemic inflammatory response and a worse prognosis in acute pancreatitis[J] Pancreatology. 2008;8(3):257–264. doi: 10.1159/000134273. [DOI] [PubMed] [Google Scholar]
- 63.Noel P., Patel K., Durgampudi C., et al. Peripancreatic fat necrosis worsens acute pancreatitis independent of pancreatic necrosis via unsaturated fatty acids increased in human pancreatic necrosis collections[J] Gut. 2016;65:100–111. doi: 10.1136/gutjnl-2014-308043. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Ince Ali Tüzün, Seven Gülseren, Koçhan Koray, et al. The course of acute pancreatitis in patients with different BMI groups[J] Pancreatology. 2022;22:348–355. doi: 10.1016/j.pan.2022.03.009. [DOI] [PubMed] [Google Scholar]
- 65.Pothoulakis I., Paragomi P., Archibugiet L., et al. Clinical features of hypertriglyceridemia-induced acute pancreatitis in an international, multicenter, prospective cohort (APPRENTICE consortium)[J] Pancreatology. 2020;20(3):325–330. doi: 10.1016/j.pan.2020.02.010. [DOI] [PubMed] [Google Scholar]
- 66.Kiss L., Fr G., Mátrai P., et al. The effect of serum triglyceride concentration on the outcome of acute pancreatitis: systematic review and meta-analysis[J] Sci. Rep. 2018;8(1) doi: 10.1038/s41598-018-32337-x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67.Pothoulakisa I., Paragomia P., Tufta M., et al. Association of serum triglyceride levels with severity in acute pancreatitis: results from an international, multicenter cohort study[J] Digestion. 2021;102(5):809–813. doi: 10.1159/000512682. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
Data included in article/supp. material/referenced in article.